Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1):21-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

REVIEWS  MIBG IN NEUROBLASTOMA 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1):21-8

Copyright © 2013 EDIZIONI MINERVA MEDICA

lingua: Inglese

Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors

Liu B. 1, 2, Zhuang H. 2, Servaes S. 2

1 Department of Nuclear Medicine, West China Hospital Sichuan University, Chengdu, Sichuan, China; 2 Department of Radiology, Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine Philadelphia, PA, USA


PDF


Meta-iodobenzylguanidine (MIBG), an analog of the adrenergic neurotransmitter norepinephrine, has proven a valuable imaging agent for neuroendocrine and neural crest tumors. Over the past 3 decades, MIBG labeled with [131I] or [123I] has been used widely in imaging of neuroblastoma and pheochromocytoma. Before September 2008 [131I]MIBG was approved as a diagnostic agent only in the US. Due to the excellent physical characteristics of [123I] for imaging with modern scintillation cameras, [123I]MIBG is theoretically more suitable than [131I]MIBG in detecting tumors. In practice, use of [123I]MIBG or [131I]MIBG for diagnostic studies depends on availability and local preference. This review compares [123I]MIBG with [131I]MIBG in imaging of neuroblastoma and other neural crest tumors and also the physical properties of relevant radioisotopes. Dosimetry and scanning protocols of [123I]MIBG and [131I]MIBG, along with their value in depicting disease extent, assessing treatment response and predicting survival are also compared. The performance of post-therapy high-activity [131I]MIBG scans in lesion detectability is also addressed.

inizio pagina